Irish Association of Dermatologists

Autumn Meeting

2nd & 3rd October, 2014
Sheraton Hotel, Athlone.
Soothing care for dry, irritated skin—
even helps to break the itch cycle

New AtoControl Face & Body Care with its unique ingredient complex, helps to intensively hydrate dry and irritated skin. The need to scratch is reduced as the skin feels more soothed and comfortable. Suitable for babies from one month.

TARGETED, HIGHLY EFFECTIVE & CLINICALLY PROVEN.

For more information and to find your nearest pharmacy visit Eucerin.co.uk
Welcome Message
from the President Dr Rosemarie Watson

I would like to extend a warm welcome to those of you attending our autumn meeting. I hope you enjoy our new venue in Athlone which should be a suitable location for dermatologists all over Ireland.

The theme for this meeting is hair. Hair - too much or too little - has been a great source of concern to mankind over the centuries. This has attracted the attention of both the beauty industry and health professionals sometimes producing treatments with very little evidence base. This meeting is very timely due to the recent major advances in this area. I am delighted to welcome our internationally renounced speakers and I am confident you will all acquire new and useful information for clinical practice. The satellite symposium on Acne and Rosacea will also I have no doubt add to our knowledge in this area.

We appreciate the support of our pharmaceutical sponsors without which we could not hold meetings of this calibre. I would also like to thank Jacqui Carroll and the executive committee and subcommittees who have been working very hard on your behalf this year. The plans are well advanced for our fiftieth anniversary celebrations next year so be sure to put April 23rd to 25th 2015 in your diary.

I hope you enjoy this meeting.

Dr Rosemarie Watson
President
IAD
The first and only approved topical treatment specifically developed and indicated for the persistent facial erythema of rosacea

- 30 minutes to a visible difference
- Sustained erythema reduction that lasts up to 12 hours
- Consistent efficacy with daily use for up to one year
Galderma sponsored Symposium

Rosacea

10.30 – 10.40 Welcome and Introduction
Professor Frank Powell

10.40 – 11.20 Pathophysiology of Erythema in Rosacea
Professor Martin Steinhoff

11.20- 12.00 Management of the Patients Journey – current and future developments
Dr. Laura Savage

12.00 – 12.30 Q & A
HUMIRA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.
**Galderma Biographical Sketches**

**Dr. Laura Savage, Leeds Dermatology Centre**

Dr Laura Savage graduated from the University of Edinburgh and trained in Dermatology within the Yorkshire Deanery. She was appointed as a Clinical Research Fellow in Dermato-Rheumatology in 2012 and is co-supervised by both Dermatologists (Dr Mark Goodfield, Dr Miriam Wittmann) and Rheumatologists (Professor Dennis McGonagle and Professor Paul Emery). Her research interests cross the boundaries of both specialties and relate to the development of strategies to detect early PsA in the dermatology arena in addition to the musculoskeletal response to skin-directed therapies. Her PhD specifically focuses upon the clinical and laboratory investigation/modulation of Th17 pathways in plaque psoriasis and subclinical psoriatic arthritis in both human tissue and mouse models. She is a member of GRAPPA and hopes to actively participate in collaborative research in the field of psoriatic disease following her PhD.

**Prof Martin Steinhoff**

Professor Steinhoff received his MD and MSc as well as PhD from the University of Marburg, Germany. In 2002, he became Assistant Professor of Dermatology at the University of Muenster, rising from assistant professor to full professor in only 6 years. He has board certifications in dermatology, venereology, phlebology and allergy from Germany, and in dermatology from the California Medical Board. Prof Steinhoff received several prestigious scientific awards for his research in Germany. To date, his group has published more than 200 articles, reviews and book chapters spanning basic science as well as clinical dermatology.

Prof Steinhoff is an established laboratory scientist who studies the substances and their receptors that cause inflammation, autoimmune disease or cancer of the skin. Beside general dermatology as a whole, his fields of clinical interests are eczema/itch, rosacea/ acne, hives (urticaria) and wound healing (ulcers). He also performs and teaches sclerotherapy and foam sclerozation for the treatment or prevention of ulcers. He has run university consultative clinics for general dermatology, in-patient clinics, a day care unit and ulcer/phlebology clinic for these conditions in Germany for almost a decade.

Prof Steinhoff moved to the United States in January 2009 when he was appointed to the UCSF Departments of Dermatology and Surgery. Besides general dermatology, Prof Steinhoff established large clinics for itch/eczema as well as rosacea; two frequently occurring dermatological diseases with substantial impact on patient quality of life. He also established a successful NIH-funded research group for neuroimmunology. Prof Steinhoff is also principal investigator of various clinical trials, some of them based on his basic research results. Prof Steinhoff started his position as Professorial Chair of Dermatology and Director of the UCD Charles Institute at University College Dublin in January 2014.
After 2 starter doses, 1 dose of Stelara® every 12 weeks can reliably control the signs and symptoms of psoriatic arthritis.1
Irish Association of Dermatologists  
Autumn meeting  
Thursday 2nd & Friday 3rd October 2014

Thursday 2nd October 2014  
Sheraton Hotel, Athlone

9.30am  Registration
10.30am-12.30pm  Galderma Satellite Symposium  
"Rosacea"
12.30pm-2.00pm  LUNCH & EXHIBITION

IAD PROGRAMME

2.00pm-2.45pm  Dr Andrew Messenger  
‘What’s new in hair disease?’  
Consultant Dermatologist  
Royal Hallemshire Hospital, Sheffield

2.45pm- 3.30pm  Dr Vicky Jolliffe  
‘Hair Loss Top Tips for Clinical Diagnosis’  
Reader in Postgraduate Medical Education and Honorary Consultant Dermatologist  
Royal London Hospital/Queen Mary University of London, London.

3.30pm – 4.00pm  COFFEE & EXHIBITION
4.00pm –4.45pm  Dr Joe O’Connor & Dr Maurice Collins  
‘The Current Management of Androgenetic Alopecia’  
Consultant Surgeons  
Hair Restoration Blackrock, Co. Dublin

5.00pm – 6.00pm  IAD Business Meeting
7.30pm  IAD CONFERENCE DINNER

Friday 3rd October 2014  
Sheraton Hotel, Athlone

9.30 – 10.45am  Registrars’ Symposium - Rogers Prize
10.45am  COFFEE & EXHIBITION
11.30 – 1.00pm  Case presentations
1.00pm – 2.00pm  LUNCH
ANTHELIOS XL
Ultra-light 50+ SPF
Even approved by men

EVEN MORE PROTECTION: LONG UVA'S+UVA+UVB

- Very water-resistant
- Photostable
- Ultra-light 50+ SPF
- Non-comedogenic
- Persian-free
- Fragrance-free

EVEN MORE COMPLIANCE: LIGHTER TEXTURE

[Images and text related to product benefits]

La Roche-Posay: recommended by Dermatologists worldwide
Biographical Sketches

Dr Andrew Messenger
Andrew Messenger is a consultant dermatologist to Sheffield Teaching Hospitals and Sheffield Children’s Hospital. He has a longstanding clinical and research interest in hair biology and disorders of hair growth. He was a founder member of the European Hair Research Society and its president 2004-6. He was president of the 7th World Congress of Hair Research held in Edinburgh in 2013.

Dr Joseph O’Connor MB, BCh, BAO, FRCS RCPS Glasg, FRCS Edin, FRCS Eng, FRCSI.
Consultant Surgeon
Dr O’Connor was educated at Rockwell College, studied Medicine at University College, Dublin and interned at St Vincent’s Hospital. He was subsequently appointed lecturer at the University of Glasgow. He then spent a period as a researcher in cardiovascular and liver transplant surgery and has contributed to the international literature on these and other subjects. His Senior Registrar General Surgery rotation included a year as Vascular Fellow at the Cardiovascular Research Center, Seattle.

Dr. O’Connor holds a Specialist Certificate in General Surgery from the Royal College of Surgeons of England. He has over 30 years experience as a Consultant Surgeon and lecturer in surgery at postgraduate and undergraduate levels. He is a fellow of the Royal Colleges of Surgeons of Glasgow, Edinburgh, Ireland and England.

Dr Victoria M L Jolliffe MA (Cantab), FRCP, FRCS(Ed), MRCGP,ARCM
Honorary Consultant Dermatologist and Reader in Postgraduate Medical Education
Royal London Hospital/Queen Mary University of London. www.drvickyjolliffe.com
Vicky went up to King’s College, Cambridge to read Classics before changing to Medical Sciences and completing her training at St Mary’s Hospital London. Prior to completing CCST in Dermatology, Vicky worked in Accident and Emergency medicine and General Practice, providing her with a broad based medical background and understanding of the primary-secondary care interface.

An Honorary Consultant Dermatologist at the Royal London Hospital since 2004, she established a regional Hair Clinic in 2012. Educational Lead for the British Hair and Nail Society, she lectures internationally on Hair Disorders and is UK representative for the Pantene Hair Research Institute. She co-authored with Professor Rodney Sinclair ‘Fast Facts-Disorders of the Hair and Nails’ (2013). She has a special interest in e-learning and is UK Course Director for the Post Graduate Diploma in Clinical Dermatology, a yearlong web-based course aimed at General Practitioners(www.londondermatology.org). An accomplished String Player, her Alopecia UK fundraising video can be viewed on www.justgiving.com/quatuorVJ

Dr Maurice Collins MB, B.Ch, BAO, DLO, FRCSI, FRCS, FRCSEd.
Consultant Surgeon
Dr Collins is Medical Director and Team Principal of Hair Restoration Blackrock. He was educated at Belvedere College Dublin and did his undergraduate medical studies at University College Dublin. After graduating as a doctor he trained in General Surgery and received his Fellowship (FRCSI) in this specialty from the Royal College of Surgeons in Ireland. Dr Collins then undertook specialist surgical training in Ear, Nose and Throat Surgery and was awarded a Fellowship (FRCS) from the Royal College of Surgeons in London. He subsequently received a further Fellowship (FRCSEd.) in Head and Neck Surgery from the Royal College of Surgeons in Edinburgh. He has practised as a Consultant Surgeon in the Blackrock Clinic for the past 20 years.

Dr Collins’ interest in hair transplant surgery started fifteen years ago and he has trained and studied internationally in this specialist subject with some of the best experts in the world. Dr. Collins and his team regularly attend, and participate in, the annual conferences of The International Society of Hair Restoration Surgery (ISHRS) and the European Society of Hair Restoration Surgery (ESHRS). Dr Collins contributes to the ISHRS Hair Transplant Forum International bi-monthly newsletter and was named Surgeon of the Month in May/June 2007.

Dr Collins has invited colleagues from around the world to HRBR in Dublin and has also attended numerous workshops in hair transplant surgery in both Europe and the United States.
Skinnies are a unique range of specialist medical garments for the treatment and management of serious conditions affecting the skin. Our range is:

- **Skinnies Silk** (antimicrobial protection)
- **Skinnies Viscose** (wet or dry wrapping)
- **Skinnies WEB** (dressing retention)

All Available On Prescription

Dermacea Ltd (Skinnies) Tel: 01562 884898  Fax: 0121 259 0292

Email: infor@skinniesuk.com  Web: www.skinniesuk.com
The Irish Skin Foundation strives to assist and support those affected with skin conditions via our community outreach activities. Below are just a few of our forthcoming events:

**Allergy & Free From Expo:**

Saturday 11th & Sunday 12th October, RDS Dublin also
Saturday 8th & Sunday 9th November, Cork City Hall

We will be on hand to support eczema sufferers, offering information, encouragement and assistance. 1-2-1 Dermatology Nurse advice available.

**Cork Skin Awareness Event:**

Saturday 15th November, The Kingsley Hotel, Victoria Cross, Cork

Free to attend public event where anyone affected by, or with an interest in skin can come alone and learn more about conditions such as eczema, psoriasis, rosacea, skin cancer. A support forum where anyone with concerns about their skin can find help and advice.

Our mission is to support in all ways possible, to advocate on behalf of, to educate all involved with, and to bring comfort to those affected by skin disease in Ireland, their families and their carers.

Telephone: 01 716 6299 | www.irishskinfoundation.ie
Dermal’s extensive experience in developing highly effective, yet cosmetically elegant treatments for application to the skin, has benefitted millions of people for over half a century.

Dermal remains committed to building on our history of successful topical innovation for the benefit of future generations.
IAD Executive

Dr Rosemarie Watson,
President,
Consultant Dermatologist
Our Lady's Children's Hospital
Crumlin, Dublin

Dr Colin Buckley,
Hon Secretary,
Consultant Dermatologist
Waterford Regional Hospital
Dunmore Road, Waterford

Dr Keith Armstrong
Hon Treasurer,
Consultant Dermatologist
Royal Hospitals
Belfast

Members of Executive

Dr Pat Podmore,
Consultant Dermatologist
Altnagelvin Hospital, Derry

Dr Olivia Dolan
Consultant Dermatologist
Royal Victoria Hospital, Belfast

Dr David Alderdice
Consultant Dermatologist
Ulster Hospital
Dundonald, Belfast

Scientific Committee

Dr Olivia Dolan
Consultant Dermatologist,
Royal Victoria Hospital, Belfast

Dr Susannah Hoey
Consultant Dermatologist
Royal Victoria Hospital, Belfast

Dr Andrea Corry
Consultant Dermatologist
Belfast City Hospital, Belfast

Dr Anne-Marie Tobin
Consultant Dermatologist
Tallaght Hospital, Dublin

Dr Fergal Moloney
Consultant Dermatologist
Mater Hospital, Dublin

IAD Past Presidents

1965/7 Dr R. Hall, Belfast, who was followed by:
1967/9 Dr D.O'C Donelan
1969/71 Dr J.M. Beare
1971/3 Dr D.M. Mitchell
1973/5 Dr D.B. Buckley
1975/7 Prof D. Burrows
1977/9 Dr F.O.C. Meenam
1979/81 Dr Agnese M.T. Kelly
1981/3 Dr Count H. Viani
1983/5 Dr Grace Allen
1985/7 Dr Marjory Young
1987/9 Dr Roddy Matthews
1989/91 Dr David O'Gorman
1991/3 Dr Rory Corbett
1993/5 Prof Sarah Rogers
1995/7 Dr E.A. Bingham
1997-9 Dr. Fergus Lyons
1999-01 Dr Clifford McMillan
2001-3 Prof Frank Powell
2003-5 Dr Raymond Fulton
2005-7 Prof Louise Barnes
2007-9 Dr Hilary Jenkinson
2009-11 Dr Gillian Murphy
2011-13 Dr Pat Podmore
2013-Present Dr Rosemarie Watson
Treatment of Advanced Basal Cell Carcinoma (aBCC)*
### Registrars’ Symposium - Rogers Prize

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>01.</td>
<td>9.30am</td>
<td>Assessment of a visual risk communication aid used to support patients in deciding about biological therapy. M. Dolan, M. Connolly &amp; A. Tobin</td>
</tr>
<tr>
<td>02.</td>
<td>9.42am</td>
<td>Attitudes Towards Sun Exposure In Inflammatory Bowel Disease Patients Taking Azathioprine. E. Gilhooley, A. Farrelly, M Connolly, A. Tobin.</td>
</tr>
<tr>
<td>03.</td>
<td>9.54am</td>
<td>Patient perspectives on absolute and relative risk of cardiovascular disease in psoriasis using the QRISK algorithm. R. Hellen, R. O'Connor, M. Connolly, AM. Tobin. Adelaide and Meath Hospital, Tallaght, Dublin 24</td>
</tr>
<tr>
<td>04.</td>
<td>10.06am</td>
<td>Hidradenitis Suppurativa and Crohn's Disease : A Case Series  S.Kirthi, R Hellen, R O’Connor, M Connolly, D McNamara, AM Tobin</td>
</tr>
<tr>
<td>05.</td>
<td>10.18am</td>
<td>Quality of life in Irish female patients with lichen sclerosus et atrophicus NicDhonncha E, Foley CC, Laing M,Markham T, Murphy A, Marren P Dermatology Department, University College Hospital, Galway</td>
</tr>
<tr>
<td>06.</td>
<td>10.30am</td>
<td>Clustered tender cheek nodules - a case of hereditary leiomyomatosis and renal cell cancer syndrome.  Clowry J, Collins P St Vincent's University Hospital, Elm Park, Dublin 4, Ireland</td>
</tr>
</tbody>
</table>
Duac is indicated for mild to moderate acne vulgaris, particularly inflammatory lesions.

Duac Safety Information:
- Duac Once Daily Gel is contraindicated for patients with known hypersensitivity to clindamycin, benzyl alcohol, parabens, or any of the ingredients in the formulation.
- Treatment with Duac should not exceed more than 16 weeks of continuous use.
- Duac is not recommended for use in children under 12 years of age.
- Skin and subcutaneous tissue disorders: at the site of application: very common (≥1/100) undesirable effects include erythema, peeling, and dryness (generally reported as 'mild' in severity).
- Please refer to the Duac SPC on emermed.co.nz for full information on contraindications, special warnings and precautions for use, and undesirable effects.

Put Duac 5% to the test against your usual topical acne combination therapy.

Use Duac daily to keep active lesions from becoming worse and to prevent new lesions from forming. Use Duac morning and evening, before and after cleansing. Apply once daily to facial skin, including the forehead, nose, and chin. Shape the once daily application by using one dose to the forehead, one dose to the nose, and one dose to the chin. The use of Duac should not exceed more than 16 weeks of continuous use.
Rogers Prize

Assessment of a visual risk communication aid used to support patients in deciding about biological therapy.
M. Dolan, M. Connolly & A. Tobin.

Introduction:
Communicating risk often proves challenging. Evidence indicates that people derive only the ‘gist’ from risk information, that assessment of risk can be influenced more by emotions than facts, and that people have a tendency to underestimate commonplace risk and overestimate rare risk. In this context, we decided to assess a visual risk communication aid (The Paling Perspective Scale ©) recently introduced to our practice as an adjunct to clinical consultation, to support patients in making choices with respect to two approved groups of biologic agents targeting tumour necrosis factor (TNF): anti-TNF monoclonal antibodies (adalimumab and infliximab), and sTNF receptors (etanercept).

Objectives:
We sought to investigate whether patients found this tool easy to understand, helpful in appreciating the potential side effects of treatment, and useful as an aid to decision making.

Methods:
The Paling Perspective Scale is a single page graphical representation, incorporating a histogram to portray risks of differing magnitude on a logarithmic scale. The risks associated with the TNF antagonists are depicted alongside more familiar risks such as death by motor vehicle in Ireland and risk of non-melanoma skin cancer, for comparative purposes to assist patients in evaluating the risks associated with treatment. The scale also incorporates verbal descriptors and includes a separate pictograph illustrating the risk of lymphoma expressed in a frequency format. Ten patients who received this scale as part of the decision making process were asked to complete a questionnaire.

Conclusions:
Ninety percent of patients found the scale easy to understand. All patients found the scale helpful in understanding the potential side effects of biological treatment. Seventy percent of patients thought the scale improved their ability to decide whether or not to commence a biologic treatment. However, patients documented the trust they still place in their doctor’s view. The assessment of this tool is ongoing.

Evidence suggests that presenting probabilistic information graphically and numerically, promotes understanding and we propose ways the scale could be refined to further enhance patients’ understanding of risk associated with biologics and inform their choices.

Attitudes Towards Sun Exposure In Inflammatory Bowel Disease Patients Taking Azathioprine.
E. Gilhooley, A. Farrelly, M Connolly, A. Tobin.

Introduction:
Immunosuppressive medications such as azathioprine are being used in patients with inflammatory bowel disease (IBD) patients in order to promote clinical remission[1]. Ongoing and past exposure to thiopurines, such as azathioprine, significantly increase the risk of non-melanoma skin cancer (NMSC) in patients with IBD, even before the age of 50 years[2].

Objective:
To examine the attitudes towards sun protection in patients taking azathioprine.

Methods:
Patients attending an inflammatory bowel disease outpatient clinic were asked to complete a questionnaire.

Results:
54% (27/50) of patients who completed this questionnaire were aware of the importance of sun protection measures with azathioprine. Of the 54% of patients aware of the need for sun protection measures only 18% (5) reported wearing sun protection factor on a daily basis. 46% (23/50) reported following sun protection strategies such as wearing protective clothing, hats and sunglasses. 52% (26/50) of patients who carried out this questionnaire frequently go on sun holidays. The Fitzpatrick skin classification of the patients sampled were as follows; Type I 22%, Type II 34%, Type III 32%, Type IV 10%, Type V 6%, Type VI 2%.

Conclusion:
IBD-specific, evidence-based guidelines for NMSC prevention have not yet been established. As for the general population, current recommendations include sun avoidance, use of broad-spectrum sun protection and minimisation of other risk factors of NMSC. Patients should be educated about the increased risk of NMSC at the initiation of immunosuppression and counselled on sun protection strategies.

References:

Patient perspectives on absolute and relative risk of cardiovascular disease in psoriasis using the QRISK algorithm.
The Adelaide and Meath Hospital, Tallaght, Dublin 24

Abstract:
Background: Psoriasis is an inflammatory condition with an increased risk of cardiovascular disease. The National Psoriasis Foundation recommends screening at least every 2 years for patients over 40. QRISK©2-2014 is a cardiovascular risk algorithm derived from a UK population. It measures a patient’s absolute risk of having a cardiovascular event over 10 years and their relative risk compared to healthy controls. It may perform as well as the Framingham algorithm and may have more accurate results as it considers ethnicity, body mass index, quantifies smoking and includes family history and co-morbidities. Rheumatoid arthritis is included as a
risk factor and we wished to see how this risk score would perform in patients with psoriasis. In addition, the equivalent ‘Heart Age’ may be a beneficial tool for communicating relative risk to patients.

Methods:
18 patients have been recruited to date from a single dermatology department. We measured their height, weight, blood pressure, lipids and calculated PASI and DLQI. Absolute and relative risk of a cardiovascular event over 10 years was estimated using the QRISK®2-2014 score. Equivalent ‘Heart Age’ was also calculated. Patients completed questionnaires to determine their knowledge of co-morbidities, modifiable risk factors and the likely impact of relative risk on modifiable risk factors such as weight and smoking.

Results:
A total of 18 patients (66.6% men and 33.3% women) were included. Ages ranged from 30-62 years with an average of 46 years. No patients were classified as high risk. The average absolute 10-year risk of cardiovascular event was 6.88%. The average relative risk was 1.91. On average, patients scored 5.6 years older by their equivalent ‘Heart Age’. 77.8% of patients were unaware that psoriasis is associated with greater cardiovascular mortality.

Conclusions:
QRISK®2-2014 is a beneficial tool in estimating cardiovascular risk in psoriasis patients and identifies modifiable risk factors essential for the primary prevention of cardiovascular events. Many of our patients were not aware that psoriasis is associated with increased cardiovascular mortality. Relative risk presented as an equivalent ‘Heart Age’ may be a beneficial adjunct to motivate changes in lifestyle and aid clinicians in screening for cardiovascular risk factors.

Reference:

■ Hidradenitis Suppurativa and Crohn’s Disease: A Case Series
S.Kirthi, R Hellen, R O’Connor, M Connolly, D McNamara, AM Tobin

Introduction:
Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent, painful abscesses, nodules and draining sinus tracts with bands of severe scar formation. Cutaneous Crohn’s Disease (CD) may also present with similar skin lesions and CD and HS occur together at a rate that varies from 0.6% to 38% based on isolated case reports. A recent cytokine and leukocyte profiling by H.H van der Zee et al demonstrated raised TNFα, IL-1β and IL-10 in tissue samples of HS patients suggesting a common underlying pathology for both conditions.

Aims:
We wished to examine the overlapping syndrome of Crohn’s Disease and Hidradenitis Suppurativa in an Irish cohort.

Methods:
Cases with HS and CD were identified by HIPE Code at Tallaght Hospital from 1990-2014. A retrospective chart review was performed of all cases.

Results:
In total, 4 patients with both HS and CD were identified. 50% were female. The median age of diagnosis for both conditions was 31 years. In all 4 cases, CD had preceded the diagnosis of HS, with a median interval of 34.5 months to HS diagnosis. 100% of patients smoked. Of note, 50% of patients had additional autoimmune conditions, 1: psoriasis and pyoderma gangrenosum, 1: ankylosing spondylitis. Despite a high BMI being associated with HS, only 1 patient (25%) in this cohort had a BMI of >30. Of note, no patients had a family history of HS. All patients required treatment with a TNF-alpha inhibitor in addition to standard antimicrobial therapy. 75% of patients (3 of 4) had an improvement of Hurley’s score on commencing anti-TNF therapy. This is the largest case series to date reported in the literature for an Irish cohort to our knowledge.

Conclusion:
Our cohort suggests that combined HS and CD syndrome affects young smokers and is frequently associated with other autoimmune conditions. Most will require anti-TNF alpha therapy to control symptoms. For those who do not respond, new therapeutic agents are eagerly sought, and further investigation with regard to interleukin 1 blockade is definitely worth investigating to treat combined CD and HS.

Reference:
1. Br J Dermatol. 2011 Jun;164(6):1292-8. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. van der Zee HH1, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, NicDhonncha E, Foley CC, Laing M, Markham T, Murphy A, Marren P

■ Quality of life in Irish female patients with lichen sclerosus et atrophicus
NicDhonncha E, Foley CC, Laing M, Markham T, Murphy A, Marren P
Dermatology Department, University College Hospital, Galway

Introduction:
Lichen sclerosus et atrophicus (LSA) is a chronic inflammatory dermatosis, more commonly occurring in women, which mainly affects the anogenital region. The most frequently reported symptoms are pruritus, discomfort, dysuria and dyspareunia. To date, there is little published data on the effect of LSA on patient quality of life (QOL).

Objectives:
To investigate the health-related QOL of a sample of Irish women with LSA using standard screening questionnaires.

Methods:
Patients attending our hospital with a diagnosis of LSA were identified from the hospital letter database (n=102). Patients were excluded if they had never attended Dermatology (n=4), if they had no pending Dermatology appointment (n=54) or if they did not have biopsy-proven LSA (n=8). The remaining patients (n=36) were offered the opportunity to participate in the study between January 2014 and June 2014. The included patients completed 2 anonymous questionnaires – the Dermatology Quality of Life Index (DLQI) and the Skindex-29.

Results:
Complete data was available on 26 patients with biopsy-proven LSA. Median age at presentation was 59.2 years (mean 55.2, range
12.5-76.8). Median duration of symptoms at time of initial presentation was 2 years (mean 3.6, range 0.3-10).

DLQI scores ranged between 0-10, with a mean score of 3.31. The impairment in QOL was none in 9/26 patients (35%), mild in 13/26 (50%) and moderate in 4/26 patients (15%). No patients reported severe impairment in QOL.

The studied patients had a mean total Skindex-29 score of 26.57 indicating mild impairment of health-related QOL overall. Severe impairment (score >44) was reported in 4/26 (15%), moderate (score 32-43) in 6/26 (23%), mild (score 25-31) in 4/26 (15%) and little (score<25) in 12/26 (46%). Domain scores for symptoms, emotions, and functioning were 37.78, 24.42, and 21.23 respectively.

Conclusion:
Lichen sclerosus et atrophicus is associated with impairment of quality of life in our patient population. While the majority of patients had mild impairment in quality of life, a smaller proportion of patients had severe impairment in quality of life. Previously published studies have shown at least moderate impairment in quality of life in association with LSA1.

References:

Clustered tender cheek nodules – a case of hereditary leiomyomatosis and renal cell cancer syndrome.
Clowry J, Collins P
St Vincent's University Hospital, Elm Park, Dublin 4, Ireland

Introduction:
A 41 year old male presented with an approximate 20 year history of multiple, non mobile, firm, flesh coloured folliculocentric nodules in a clustered distribution on his lateral right cheek. The size of the lesions ranged from from 3-5mm. These were occasionally tender on exposure to the cold. He had no similar lesions elsewhere and was otherwise asymptomatic. He had no additional medical history. Family history was notable for early onset uterine fibroids in the patient’s sister and a paternal aunt, who also developed uterine and renal cancer in her 70s. He had two children who were healthy and well.

Histopathology revealed a benign dermal spindle cell lesion, consisting of bundles of smooth muscle cells with cigar-shaped nuclei. The appearances were consistent with a benign piloleiomyoma.

The patient proceeded to have sequence analysis of genomic DNA. Results demonstrated heterozygosity for the c.301C>T; p(Arg101*) pathogenic mutation in exon 3 of the fumarate hydratase gene. This is an autosomal dominant mutation consistent with a diagnosis of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome.

This is a rare autosomal dominant condition characterised by cutaneous and uterine leiomyomatata and renal tumours in 10-16% of cases.1

Patients often first present to dermatologists, since cutaneous leiomyomatata are the earliest and most common manifestation. The mean age of onset is 25 years.2 They are found in approximately 76% of cases,2 although a higher penetrance has been reported in males.1

To date, the patient has been referred for genetic counselling and has had a normal renal ultrasound. He has declined surgical excision of his cutaneous piloleiomyoma. Ongoing surveillance has been arranged with the urology service.

TRUST in HUMIRA -

11 YEARS OF SAFETY DATA IN LABEL

10 INDICATIONS — THE MOST OF ANY SELF-ADMINISTERED BIOLOGIC

MORE THAN 85 COUNTRIES

17 YEARS OF CLINICAL TRIAL EXPERIENCE, BEGINNING WITH RHEUMATOID ARTHRITIS (RA)

71 CLINICAL TRIALS IN THE LARGEST PUBLISHED ANKYLOID SPONDYLITIS FACTOR (ASF) CROSS-RADICAL SAFETY DATABASE
An unmatched legacy.

MORE THAN 760,500 PATIENTS CURRENTLY TREATED WORLDWIDE* MORE THAN 23,000 PATIENTS IN GLOBAL CLINICAL STUDIES* HUMIRA at all moments abbvie
Eau Thermale Avène

XeraCalm A.D

Helps to relieve itching by 97%*

* Helps to reduce redness
* Stimulates skin’s natural defences
* Helps to restore the skin’s barrier

Sterile Cosmetics 0% Paraben Preservative

Laboratoires dermatologiques Avène

*Data on file 2013: Clinical tolerence study carried out on 32 subjects aged 7 months to 9 years, 2 applications per day for 29 days of Xeracalm A.D cream
Case presentations

01. 11.30am
Congenital segmental alopecia - Atypical Focal Facial Dermal Hypoplasia?
Dr Lorraine Jennings1, Dr Alan Irvine2 and Dr Sinead Collins1
1 Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Co. Louth
2 Department of Dermatology, Our Ladies Children’s Hospital, Crumlin, Dublin

02. 11.40am
Hirsutism in a teenager
MA McAleer, E O’ Dea, R Watson Our Lady’s Children’s Hospital Crumlin

03. 11.50am
Takotsubo cardiomyopathy and telogen effluvium associated with severe broncho-pneumonia
S. McCarthy, I. McDonald, C. Fahy, N. Mahon, F.J. Moloney
Department of Dermatology, Mater Misericordiae University Hospital

04. 12.00pm
Successful treatment of a patient with Chronic Mucocutaneous Candidiasis due to a gain-of-function mutation in STAT-1 with JAK1/2 inhibitor ruxolitinib.
Eleanor Higgins1 Conleth Feighery2, Maeve McAleer3 Desa Lilic 4 Alan D.Irvine1, 3, 5.
1 Dermatology 2 Immunology, St James’s Hospital,
3 National Children’s Research Centre, Our Lady’s Children’s Hospital, Dublin 4 Primary Immunodeficiency Group, Institute of Cellular Medicine Newcastle University, UK.
5 Department of Clinical Medicine, Trinity College Dublin.

05. 12.10pm
Lichen Planopilaris with Facial Papules
A. Flynn, B. Wynne. St James’s Hospital, Dublin

06. 12.20pm
Kerion induced scarring Alopecia
Flynn, B. Wynne. St James’s Hospital, Dublin

07. 12.30pm
A newborn referred with blistering
W. Abdelrahman, S Clements, S Hoey
Dept of Dermatology, Royal Victoria Hospital, Belfast, Northern Ireland

08. 12.40pm
Treatment of cutaneous metastatic melanoma with topical diphencyprone - a case report
I. McDonald, F.M. Keane, J.A. McCaffrey, F.J. Moloney
Department of Dermatology, Mater Misericordiae University Hospital

09. 12.50pm
A case of melanonychia in a child.
RH El-khayat, M Y Walsh, A Rashid, K McKenna 1.
1 Department of Dermatology 2 Department of Pathology
3 Department of Plastic Surgery, Belfast Health and Social Care Trust.
A 13-year-old South-African male presented to our Paediatric Dermatology clinic with right-sided scalp alopecia that had been present since birth. He was the product of spontaneous normal delivery. There was no relevant past medical or family history. His parents were non-consanguineous.

Examination revealed a well-demarcated whorled pattern of alopecia on the right parietal scalp and vertex, associated with an asymmetrical underlying bony prominence. There were several circular atrophic scars with anetoderma in a linear pattern along the edge of the parietal alopecia, which had also been present since birth. An area of alopecia was noted extending to the right eyebrow. All sites of alopecia-involved skin had a doughy, extensile consistency. The patient was otherwise developmentally normal. His nails and teeth were normal, except for some bilateral incisor overcrowding. No skeletal abnormalities were detected.

Diagnostic punch biopsies were performed from the affected scalp and from an area of clinically unaffected skin. There were no visible hair follicles in the affected areas, and no apparent difference in elastic staining between the samples.

Congenital alopecia is associated with a wide range of genetic conditions or may be a marker for an underlying metabolic disorder, which may impact on the mental and physical development of a child, emphasising the importance of early diagnosis.

This case represents a congenital, unilateral, scarring alopecia with underlying soft tissue abnormality, in an otherwise healthy teenager. The distribution and atrophic scarring is suggestive of focal facial dermal hypoplasia (FFDH) Type III (Setlifes Syndrome), a rare form of ectodermal dysplasia. However, the associated textural changes seen in this case are atypical and not previously reported in this condition. A single case report of localised Ehlers-Danlos exists also, with similar features to our case and without any systemic features of the disease.

We present this child with segmental alopecia with hypertextuensibility as an atypical case of focal dermal hypoplasia in the absence of a more unifying diagnosis. Further diagnostic suggestions are welcome.

References:

Hirsutism in a teenager
MA McAleer, E O’Dea, R Watson, Our Lady’s Children’s Hospital Crumlin
Abstract:
A 15-year-old girl presented with severe hirsutism. She had insulin resistance secondary to a mutation in the tyrosine kinase domain of the insulin receptor. She was obese and had polycystic ovarian syndrome.

The patient had previously tried to improve her hirsutism with intense pulsed light treatment at a local laser centre without success. Anti-androgen therapy had been ineffective. Epilation in conjunction with topical effeminate 15% cream had also proved unsuccessful.

The teenager suffered severe psychological morbidity and social difficulties secondary to the hirsutism. She reported anxiety and depressive symptoms.

When she presented to our service she had ben avoiding leaving her bedroom for a year, which had a considerable impact on her schooling.

Treatment was commenced with the Alexandrite 775nm laser to the most visibly evident hirsute areas of the face, neck and upper chest. The patient has had 9 treatments to date. There has been an excellent improvement, with an 80% reduction in hair. The patient’s psychological health has significantly improved. She has returned to school and can socialise with her peers.

Multiple studies have demonstrated effective hair removal with the long-pulsed alexandrite laser at fluences of 10-40 j/cm2 and pulse durations of 2-20 ms. At fluences of 20-40 j/cm2, several studies have reported hair reduction of 70-80% after multiple (at least 3-5) treatments.

In adolescent females hirsutism is associated with a decreased quality of life, a higher prevalence of anxiety disorder, and lower self-esteem. Higher levels of hair growth have been significantly correlated with a lower quality of life and symptoms of anxiety and depression. Laser treatment of facial hair in 70 women significantly improved their quality of life scores.3

Our case highlights the importance of early and effective treatment of hirsutism, particularly in adolescents, in an attempt to reduce the adverse psychological and social impact of the disease.


Takotsubo cardiomyopathy and telogen effluvium associated with severe broncho-pneumonia
S. McCarthy, L McDonald, C Fahy, N Mahon, FJ Moloney
Department of Dermatology, Mater Misericordiae University Hospital

Introduction:
The pathophysiology of takotsubo cardiomyopathy (broken-heart syndrome) is poorly understood. Both it and telogen effluvium are reactive processes preceded by similar triggers including emotional and physical stressors, or medications. We describe the first report of both conditions occurring concurrently following an episode of severe bronchopneumonia.

Case History:
A 67-year-old female was admitted to a tertiary referral centre in March 2013 with community-acquired pneumonia secondary to haemophilus influenza. She was treated with vancomycin, meropenem and clarithromycin and was discharged six days later. She re-presented two weeks later with symptomatic persistent lingular pneumonia and was treated with moxifloxacin. Six weeks post discharge, the patient presented with sudden onset of dyspnoea. ST elevation was noted on her ECG antero-laterally. Coronary angiogram showed extensive antero-apical hypokinesia, with little coronary artery disease, consistent with takotsubo cardiomyopathy. During her in-patient stay she noted sudden onset diffuse scalp hair shedding. She had no personal or family history of alopecia. Examination revealed hair thinning over the vertex and frontal scalp with no inflammation or scarring evident. She had a positive hair pull test with increased numbers of telogen hairs. Thyroid function and iron stores were normal. A clinical diagnosis of acute telogen effluvium was made and the patient reassured. At clinic review four months post discharge she had full hair regrowth. By that time, her cardiac function had returned to normal.

Discussion:
Medications have been implicated in cases of both telogen effluvium and takotsubo cardiomyopathy, however, the presumptive trigger in our case was her severe bronchopneumonia and resultant stresses. While the interval between inciting event and onset of hair shedding is dictated by the individual patient's telogen hair cycle length, the time scale in relation to development of takotsubo cardiomyopathy, after exposure to an emotional or physical stress, is less predictable. Both resolved without sequelae, an
indication of the favourable prognosis seen with both diagnoses. The two conditions developing in concurrence and the temporal association with her illness suggest that the same stress-induced catecholamine release, with toxicity to and subsequent stumming of the myocardium thought to result in broken-heart syndrome may involve similar neurotransmitter and hormonal pathway changes inducing cardiac in the hair follicle.1

1. Satoshi Kurisu, Yasuki Kihara, Taka-Ishu cardio-myopathy: Clinical presenta-

Successful treatment of a patient with Chronic Muco-cutaneous Candidi-
dasis due to a gain-of-function mutation in STAT1 with JAK1/2 inhibitor ruxolitinib.

Eleanor Higgins Conleith Feighery1, Maive McAleer1 Desa Liic1 Alan D. Irvine1,2,3
‘Dermatology Immunology, St James’s Hospital, ‘National Children’s Re-
search Centre, ‘Our Lady’s Children’s Hospital, Dublin

Primary Immunodeficiency Group, Institute of Cellular Medicine Newcas-
tle University, UK ‘Department of Clinical Medicine, Trinity College Dublin.

Abstract:

RW.CITE((194 XinG.L. 2014)) did demonstrate the role of cytotoxic T lympho-
cytes in alopecia areata (AA) and provided important mechanistic informa-
tion on the pathogenic T-cell inflammatory pathways in this autoimmune condition. They described three patients with AA successfully treated with the oral Janus kinase (JAK) family protein tyrosine kinase inhibitor ruxolitinib. We further show the potential utility of ruxolitinib for AA occurring in the wider context of a genetic autoimmune/immunodeficiency syndrome. We recently treated AA associated with chronic mucocutaneous candidiasis (OMIM #641612) in a 28-year-old female with ruxolitinib. Our patient had a sporadic autosomal dominant gain-of-function (GOF) mutation (heterozy-
gous c1159A>G (p.(Thr387Ala) in exon 14 of STAT1 and had a two-year his-
tory of alopecia areata. This had progressed despite previous intralesional corticosteroid injections, with greater than 40% scalp involvement. She also had recalcitrant oral candidiasis since childhood, with frequent flares de-
spite daily oral fluconazole.

STAT1 gain-of-function with such mutations may be mediated via enhanced phosphorylation resulting in gain of function of gamma interferon activat-
ing factor and subsequent aberrant IL-17 immunity. Patients with gain-of-
function STAT1 mutations also have decreased STAT3 which may explain downstream reduction of IL-17 expression. In canonical IFN-γ-JAK-STAT1 signalling; ligand engagement of the IFN-γ receptor leads to activation of receptor-associated JAK1 and JAK2.

We therefore hypothesized that JAK1/2 inhibition would target this pathway and would ameliorate both the CMC and the associated autoimmune AA phenotype in our patient. Ruxolitinib is a JAK 1/2 inhibitor approved for treatment of myelofibrosis, targeting pathogenic mutant JAK 2 pathway sig-
nalling and activation of transcription (JAK-STAT) pathways. We treated our patient with ruxolitinib 20 mg twice daily for twelve weeks (off-licence). After 2 weeks, our patient experienced dramatic hair regrowth in all affected ar-
 eas of alopecia. The hair regrowth was uniform and thick, with full regrowth at completion of treatment and this was sustained on review 3 months after completion of therapy. Our patient also reported complete resolution of oral candidiasis while on ruxolitinib treatment.

We hypothesize that correction of the GOF-STAT1 may allow restoration of STAT3-dependent production of IL-17, thus improving oral candidiasis. Xing et al highlighted the potential for further clinical evaluation for ruxolitinib and other JAK inhibitors in the treatment of AA. Our case suggests the potential therapeutic benefit of ruxolitinib in GOF-STAT1 genetic immunodeficiency autoimmune syndrome. While further evaluation on additional patients in clearly needed, this therapy may represent an ideal personalized treatment for patients with gain-of-function mutations in STAT1.


Case Summary: Lichen planopilaris (LPP) is a rare inflammatory condition that results in patchy progressive permanent hair loss mainly on the scalp. It commonly affects young adult females. Frontal fibrosing alopecia is considered a par-
ticular clinical form of LPP that primarily involves the scalp hair over the frontal hairline. Concomitant papules at different body sites are a well-
recognised feature. However, facial papules associated with Lichen Planop-
laris have only been described once in the literature. We a case of Lichen Planopilaris with facial papules.

MH, a 44-year-old woman presented with a 1-year history of facial and scalp irritation. Her General Practitioner had treated her with protopic, eumovate and diprosalic for presumed psoriasis. Clinical examination revealed scar-
ring alopecia along her frontal scalp with perifollicular erythema. There was minimal scale throughout the rest of her scalp. She also was noted to have loss of the lateral third of her eyebrows, along with prominent papules on her temples. Histopathology was consistent with lichen planopilaris. She is managed on Hydroxycholoroquine orally and Isotretinoin topically to the papules.

References:

Facial papules in Frontal Fibrosing Alopecia: Evidence of Veilus Follicle Involv-
ment.
Donati A, Molina L, Doche I, Valente NS, Romiti R
Arch Dermatology 2011 Dec; 147(12): 1444-7

Kerion Induced scarring Alopecia
Flynn, B. Wynne. St James’s Hospital, Dublin

Case Summary: We present a case of a 2-year-old boy with significant scarring alopecia due to a large kerion on his scalp.

IS age 2 years 4 months presented to Accident and Emergency with a 7-
month history of a progressive scalp kerion. He had been seen by a doctor not on the specialist registrar for dermatology. He treated him with topical steroids and it continued to progress until his presentation to hospital. The week prior to admission he had been unable to sleep due to the pain on his scalp, which was now oozing and bleeding. Clinical examination revealed a large Kerion with satellite lesions and cervical lymphadenopathy. Fungal scrapings grew Microsporum Canis. He was commenced on Oral Itracon-
azole, Nizoral Shampoo, Oral Fluociclovilicilicilic, Oral Prednisolone and Paraffin Gel. Within two weeks his scalp had significantly improved, with some mild swelling and minimal crusting. He unfortunately has a large area of scarring alopecia on his parietal scalp. He has been continued on the same treat-
ment with the addition of topical fucidin.

This case highlights the importance of Dermatology review for persistent linea capitis/kerion. Due to the delay in appropriate management this child has a large area of scarring alopecia on his parietal scalp. Given the cos-
metic and psychological effects this will have long-term, he may be a suit-
able candidate for hair transplantation.

REFERENCES

Permanent Hair Loss after Kerion Celsi
Bonnin TF, Iversen E, Krogballe K
Ugeskr Laeger 1991 Nov 41;153(45):3151-2

Hair Loss Following Kerion Celsi – A Follow-up Examination
Faged, E. K. and Jepsen, L. V. (1984), Hair Loss Following Kerion Celsi–A Follow-
up Examination. Mycoses, 27: 411–414

LICHEN PLANOPILARIS WITH FACIAL PAPULES
Dr Aoibheann Flye, Dr Bairbre Wynne
St. James’s Hospital, Dublin

Case Summary: Lichen planopilaris (LPP) is a rare inflammatory condition that results in patchy progressive permanent hair loss mainly on the scalp. It commonly affects young adult females. Frontal fibrosing alopecia is considered a particular clinical form of LPP that primarily involves the scalp hair over the frontal hairline. Concomitant papules at different body sites are a well-recognised feature. However, facial papules associated with Lichen Planopilaris have only been described once in the literature. We a case of Lichen Planopilaris with facial papules.

MH, a 44-year-old woman presented with a 1-year history of facial and scalp irritation. Her General Practitioner had treated her with protopic, eumovate and diprosalic for presumed psoriasis. Clinical examination revealed scarring alopecia along her frontal scalp with perifollicular erythema. There was minimal scale throughout the rest of her scalp. She also was noted to have loss of the lateral third of her eyebrows, along with prominent papules on her temples. Histopathology was consistent with lichen planopilaris. She is managed on Hydroxycholoroquine orally and Isotretinoin topically to the papules.

References:

Facial papules in Frontal Fibrosing Alopecia: Evidence of Veilus Follicle Involv-
ment.
Donati A, Molina L, Doche I, Valente NS, Romiti R
Arch Dermatology 2011 Dec; 147(12): 1444-7

Kerion Induced scarring Alopecia
Flynn, B. Wynne. St James’s Hospital, Dublin

Case Summary: We present a case of a 2-year-old boy with significant scarring alopecia due to a large kerion on his scalp.

IS age 2 years 4 months presented to Accident and Emergency with a 7-
month history of a progressive scalp kerion. He had been seen by a doctor not on the specialist registrar for dermatology. He treated him with topical steroids and it continued to progress until his presentation to hospital. The week prior to admission he had been unable to sleep due to the pain on his scalp, which was now oozing and bleeding. Clinical examination revealed a large Kerion with satellite lesions and cervical lymphadenopathy. Fungal scrapings grew Microsporum Canis. He was commenced on Oral Itracon-
azole, Nizoral Shampoo, Oral Fluociclovilicilicilic, Oral Prednisolone and Paraffin Gel. Within two weeks his scalp had significantly improved, with some mild swelling and minimal crusting. He unfortunately has a large area of scarring alopecia on his parietal scalp. He has been continued on the same treat-
ment with the addition of topical fucidin.

This case highlights the importance of Dermatology review for persistent linea capitis/kerion. Due to the delay in appropriate management this child has a large area of scarring alopecia on his parietal scalp. Given the cos-
metic and psychological effects this will have long-term, he may be a suit-
able candidate for hair transplantation.

REFERENCES

Permanent Hair Loss after Kerion Celsi
Bonnin TF, Iversen E, Krogballe K
Ugeskr Laeger 1991 Nov 41;153(45):3151-2

Hair Loss Following Kerion Celsi – A Follow-up Examination
Faged, E. K. and Jepsen, L. V. (1984), Hair Loss Following Kerion Celsi–A Follow-
up Examination. Mycoses, 27: 411–414
A 57-year-old man with a primary superficial spreading melanoma (Breslow thickness 2.3mm, mitotic count 4-5/10hpf), on his left lower back was treated with wide local excision in June 2011. Sentinel node biopsy revealed a single positive inguinal node. He received high dose adjuvant interferon treatment from September 2011 until October 2012. In February 2013 he presented with extensive, pigmented nodules and papules on his right buttock and hip. Histology confirmed locoregional recurrent melanoma. Imaging at that time revealed no distant metastases. He remained clinically well and screening for the BRAF mutation was negative. Multidisciplinary discussion deemed surgical resection or radiotherapy unsuitable and the option of topical immunotherapy was explored.

Treatment regime:
Following consent the patient was sensitized by the application of 2% DPCP in acetone on skin on his upper arm. 5% Imiquimod cream was applied to an area 8x8cm on the affected buttock, on two separate days. Twenty four hours later 0.1% DPCP in aqueous cream was applied and left on for 12 hours. He was reviewed weekly before further application of DPCP. 5% Imiquimod cream was applied on the day prior to review. Because of significant blistering and erythema at the site of application the concentration of DPCP was reduced to 0.05% and Imiquimod was held. After three weeks treatment the cutaneous metastases flattened from baseline. At four weeks, two nodules had resolved and at five weeks further flattening was observed. A decision to discontinue DPCP at that point was taken due to patient discomfort from localised inflammation.

Conclusions:
The management of extensive in transit metastases is difficult and must be individualized and discussed by a multidisciplinary team. Topical DPCP is an inexpensive and generally well tolerated therapeutic option for slow growing cutaneous metastatic melanoma deemed unsuitable for surgery, radiotherapy or targeted therapy.

A case of melanonychia in a child.
RH El-khayat1, M Y Walsh2, A Rashid3, K McKenna1 .
1 Department of Dermatology 2 Department of Pathology 3 Department of Plastic Surgery. Belfast Health and Social Care Trust.

Case description:
A 2-year old child, presented at the age of 3 months with pigmentation of the left great toe nail. The pigmentation has been present since birth. On examination the following were noted: Brown pigmentation across the nail fold and nail bed, as well as, multiple fine longitudinal pigmented bands. At clinic review 4 months later, the nail was reported to be brittle and the following changes to the pigmentation pattern were noted: The pigmentation in the proximal nail fold had spread more proximally, a single longitudinal pigmented wide band and pigmentation in the lateral nail fold. Subsequently, a wedge excision of eponychium was arranged. The histopathology report was inconclusive with no melanocytic lesion or melanocytes identified in the specimen.

Digital dermoscopy assessment was then carried out, which showed features in keeping with melanocytic lesion. The case was discussed at the skin cancer MDT and nail bed with nail fold limited transverse excision was recommended. The histopathology report on this occasion confirmed subungual compound naevus with no evidence of dysplasia or malignancy. Following the transverse excision, persistent abnormal pigmentation was noted. Therefore, wider excision of recurrent melanonychia with full thickness graft was performed. The histopathology report confirmed the complete excision of the compound naevus.

Discussion:
The initial wedge biopsy was inconclusive. However, the worrisome changes noted in our case on subsequent clinical reviews warranted both limited and wider excision to exclude malignant transformation arising in a benign precursor. Subungual congenital nevi are rare with less than 20 biopsy-proven cases reported. All the reported congenital subungual melanocytic nevi had a false positive Hutchinson sign (periungal hyperpigmentation with longitudinal melanonychia).

Reference :
P 01
Epidermal Protease-activated receptor-2 (PAR2) overexpression causes atopic dermatitis-like skin disease: Neuro-Epidermal Communication
1 Dept. of Dermatology and UCD Charles Institute for Translational Dermatology, Dublin, Ireland; 2 UMG Dermatology, Göttingen, Germany; 3 UCSF Dermatology, San Francisco, CA, USA; 4 UKM Dermatology, Münster, Germany; 5 UCD Center for Neuroscience, Davis, CA, USA; 6 UCSF Cardiovascular Research Institute, San Francisco, CA, USA.

P 02
Molecular and morphological characterization of the inflammatory infiltrate in Rosacea: new insights into immune pathophysiology
Timo Buhl3,4, Mathias Sulik2, Pawel Nowak2, Jörg Buddenkotte2, Ferda Cevikbas1, Cordula Kempkes1, Jerome Aubert5, Johannes J. Voegels, and Martin Steinhoff4
1 Dermatology, University of California, San Francisco (UCSF), San Francisco, CA, USA; 2 Dermatology, University of Münster, Münster, Germany; 3 Dermatology, University of Göttingen, Göttingen, Germany; 4 Charles Institute for Translational Dermatology, University of Dublin, Dublin, Ireland; 5 Molecular Dermatology, Galderma R&D, Sophia Antipolis, France

P 03
Actinic granulomas in a patient with poorly controlled diabetes mellitus: a diagnostic dilemma.
The Adelaide and Meath Hospital, Tallaght, Dublin 24

P 04
Behçet’s disease occurring within plaques of necrobiosis lipoidica
S. McCarthy, I. McDonald, C. Fahy, P. Lenane
Department of Dermatology, Mater Misericordiae University Hospital

P 05
A case of aromatase inhibitor - induced lupus erythematosus
S. McCarthy, I. McDonald, C. Fahy, P. Lenane
Department of Dermatology, Mater Misericordiae University Hospital

P 06
Pregnancy induced rosacea fulminans, what happens in subsequent pregnancies?
R. O’Connor, R. Hellen, M. Connolly, AM. Tobin.
The Adelaide & Meath Hospital, Tallaght, Dublin 24.

P 07
Two cases of significant weight loss on isotretinoin.
R. O’Connor, R. Hellen, M. Connolly, AM. Tobin
The Adelaide & Meath Hospital, Dublin
Epidermal Protease-activated receptor-2 (PAR2) overexpression causes atopic dermatitis-like skin disease: Neuro-Epidermal Communication


1 Dept. of Dermatology and UCD Charles Institute for Translational Dermatology, Dublin, Ireland; 2 UMG Dermatology, Göttingen, Germany; 3 UCSF Dermatology, San Francisco, CA, USA; 4 UKM Dermatology, Münster, Germany; 5 UCD Center for Neuroscience, Davis, CA, USA; 6 UCSF Cardiovascular Research Institute, San Francisco, CA, USA.

Protease-activated receptor-2 (PAR2) activation has been implicated in the pathophysiology of atopic dermatitis, Netherton syndrome, pruritus, as well as impaired skin barrier regulation. With the aim to study the effects of epidermal PAR-2 function on skin inflammation and itch, we generated a mouse that overexpresses PAR2 in keratinocytes only (KC-PAR2OE). Although KC-PAR2OE newborns display no overt abnormalities, they spontaneously develop dry skin, severe pruritus, and subsequently eczematous skin lesions after several weeks. Analysis of barrier function and immune response in lesional KC-PAR2OE mice revealed the hallmarks of atopic dermatitis-like skin lesions including acanthosis, parakeratosis, significant downregulation of filaggrin and other epidermal structure proteins, a mast cell- and T cell-driven inflammatory infiltrate. Of note, and in close correlation to patients with atopic dermatitis, repeated topical application of house dust mite (HDM) allergens onto KC-PAR2OE mice induced earlier and more severe lesions and pruritus in these mice (as determined by increased skin lesion score, scratching bouts, TEWL, total IgE). Our electrophysiological, morphological and molecular studies show that KC-PAR2OE mice have increased density of unmyelinated nerve fibers, increased NGF and endothelin expression levels in the skin, which may explain our increased density of unmyelinated nerve fibers, increased NGF and endothelin expression levels in the skin, which may explain the findings of higher susceptibility of KC-PAR2OE mice to pruritogens and the development of spontaneously increased pruritus. In sum, our results suggest that certain proteases and KC-PAR2 are critically involved in the pathophysiology of atopic dermatitis. KC-derived PAR2 seems to be an important link in neuro-epidermal communication with the keratinocyte-protease-PAR2 system as a forefront of sensory signaling and neuro-immune communication in inflammatory skin diseases.

Molecula r and morphological characterization of the inflammatory infiltrate in Rosacea: new insights into immune pathophysiology

Timo Buhl1,2,4, Mathias Sulka, Pawel Nowak2, Jörg Buddenkotter2, Ferda Cevikbas3, Cordula Kempkes3, Jerome Aubertz, Johannes J. Voegels, and Martin Steinhoff4

1Dermatology, University of California, San Francisco (UCSF), San Francisco, CA, USA; 2Dermatology, University of Münster, Münster, Germany; 3Dermatology, University of Göttingen, Göttingen, Germany; 4Charles Institute for Translational Dermatology, University of Dublin, Dublin, Ireland; 5Molecular Dermatology, Golderna R&D, Sophia Antipolis, France.

Rosacea is a common chronic inflammatory skin disease of unknown etiology. Thus, the treatment for rosacea is often only symptomatic and a deeper insight into the exact pathophysiology is needed. Therefore, we performed a detailed transcriptome analysis of relevant genes in rosacea subtypes (ETR, PPR, and PhR), compared to non-lesional or healthy skin. Here, we focused on the genes involved in innate or adaptive immunity, and characterized the inflammatory infiltrate using immunohistochemistry. In all rosacea subtypes, the T cell marker CD3 was increased on gene level. Using immunohistochemistry and morphometry, we found an increased infiltrate of CD4+ T cells in ETR and PPR, in particular T helper 1 (TH1) and T helper 17 (TH17) cells. In contrast, molecular markers for B cell activation were only occasionally increased, and immunohistochemistry confirmed B cells to be only occasionally localized in single patients with PPR or PhR. High expression levels of chemokines and cytokines known to be involved in immune cell recruitment and activation of macrophages and mast cells were also observed. In sum, the immune response in rosacea shows a TH1/TH17 expression profile, although slight differences between each subtype exist. Moreover, B cells are only occasionally observed, indicating different trigger factor leading to rosacea. Of innate immune cells, macrophages and mast cells were abundantly present, neutrophils only in pustules, correlating well with transcriptome data. No differences were found for Langerhans cells, NK cells or basophils in rosacea patients compared to controls. Our data give a better understanding about the underlying immune pathways in the pathophysiology of rosacea that may lead to novel, more specific therapies for this frequent chronic inflammatory skin disease.

Actinic granulomas in a patient with poorly controlled diabetes mellitus: a diagnostic dilemma.

The Adelaide and Meath Hospital, Tallaght, Dublin 24

Actinic granuloma (AG) is an uncommon granulomatous condition which is characterized by annular plaques on actinically damaged, photo-exposed skin.

We report a case of a 48-year-old woman who presented with a five month history of a pruritic photo-distributed, eruption on her face, arms, chest wall and upper back. The patient also had poorly controlled type II diabetes with an elevated haemoglobin A1c (62 mmol/mol; reference range < 53 mmol/mol). She also had a positive antinuclear antibody (ANA) and anti-UtRNP antibodies. Oral and topical steroids had not improved her symptoms.

Histology showed necrobiosis of collagen with surrounding palisading histiocytes, occasional giant cells and a mild perivascular lymphohistiocytic infiltrate. These findings were consistent with a number of differential diagnoses including granuloma annulare, necrobiosis lipoidica, actinic granulomas and interstitial granulomatous dermatitis with arthritis.

The patient was treated as eruptive granuloma annulare and commenced on bath PUVA. After two exposures, she became progressively symptomatic with new lesions and phototherapy was discontinued. This development was more consistent with a diag-
nosis of actinic granulomas and the patient was commenced on hydroxychloroquine 200mg twice daily with photoprotection. After nine months of treatment, her plaques had flattened with reduced erythema and pruritus.

We report this case as a diagnostic dilemma of actinic granulomas mimicking granuloma annulare in a patient with poorly controlled type II diabetes.

**Behçet's disease occurring within plaques of necrobiosis lipoidica**

S. McCarthy, I. McDonald, C. Fahy, P. Lenane  
*Department of Dermatology, Mater Misericordiae University Hospital*

**Abstract:**
We describe the first case of behçet's ulceration occurring within plaques of pre-existing necrobiosis lipoidica.

**Case History:**
A 61 year old lady presented with acute onset of painful lower limb ulceration in the setting of established necrobiosis lipoidica diabeticorum and a 45 year history of beçhets disease.

She was initially diagnosed at the age of 16 when she developed oral and genital ulceration. She has a strong family history of the disease, which affects her sister, brother and daughter. Colchicine treatment was commenced in 2002 to good affect and he developed infrequent flares of the disease up to 2013.

In her early 40's she was diagnosed with necrobiosis lipoidica, in the absence of diabetes mellitus. Erythematous papules developed on her anterior shins bilaterally, without ulceration, and formed atrophic plaques. Topical steroids were commenced initially and subsequently topical tacrolimus was prescribed. In late 2013 she developed breakdown of the areas of necrobiosis lipoidica on her lower limbs. The areas of ulceration were deep and tender with an overhanging inflammatory edge and malodourous discharge. She was prescribed oral erythromycin for ten days, and her colchicine was recommenced. The lesions, however, deteriorated rapidly. Multiple skin biopsies of the inflammatory margin were performed which showed acute inflammatory and vascular changes, and a neutrophilic pustular dermatosis, most consistent with pyoderma gangrenosum-like behçet's ulceration within plaques of necrobiosis lipoidica.

**Discussion:**
Behçet's disease is a systemic vasculitis of small and large vessels affecting both veins and arteries. It is characterized by recurrent oral aphthae, followed by genital ulcers, skin lesions, arthritis, uveitis, thrombophlebitis, and gastrointestinal and central nervous system involvement. Cutaneous lesions can include pyoderma gangrenosum-like lesions, and pathergy. Necrobiosis lipoidica (NL) is a chronic granulomatous disease. It is usually diagnosed clinically. Erythematous papules develop on the anterior aspect of the lower extremities that can coalesce to form atrophic plaques with telangiectasia. While ulceration is common in NL, the rapid deterioration in this case was unusual. It is possible that pathergy has a role to play in its development within plaques of NL.

**A case of aromatase inhibitor - induced lupus erythematosus**

S. McCarthy, I. McDonald, C. Fahy, P. Lenane  
*Department of Dermatology, Mater Misericordiae University Hospital*

**Introduction:**
Subacute lupus erythematosus is typically associated with photosensitivity and annular or papulosquamous lesions occurring on sun – exposed skin. Positive anti – Ro antibodies are associated with this disorder, which is also associated with potential drug induction or exacerbation and as a paraneoplastic phenomenon.

**Case Report:**
We report the case of a 91-year old female, referred to the tertiary referral department of dermatology in 2012. She was being treated for ER positive breast cancer with an aromatase inhibitor, anastrazole and a rash developed two weeks post induction.

The primary lesion was an erythematous annular rash and it affected the face, neck, upper limbs, chest and left breast, which was tender to palpation. Anti - Ro antibody was positive and anti – histone antibody was negative. Initial treatment with oral steroids and antibiotics had a positive response however there was recurrence of the rash on cessation of steroid therapy. The initial differential diagnosis included drug induced lupus erythematosus, erythema multiforme and vasculitis. Histopathology of a biopsy showed features which suggested erythema multiforme or a fixed drug eruption. Clinically however, the rash was most in keeping with drug-induced subacute lupus erythematosus. The aromatase inhibitor was the likely culprit. In early 2013, the patient re-presented with recurrence of subacute lupus erythematosus following initiation of tamoxifen treatment.

**Discussion:**
The induction of cutaneous lupus by drugs, which are associated with treatment of breast carcinoma, has been previously reported. Tamoxifen was shown to induce subacute lupus in two women attending dermatology services in Nancy, France.1 Trancart et al reported the first case of anastrazole induced subacute lupus in a 73 yr old woman with breast cancer in 2007.2 The development of subacute lupus was thought to primarily be secondary to drug induction due to the chronology of cutaneous disease and commencement of hormonal treatment for breast carcinoma. Considering the rapid development of new, advanced treatments for various carcinomas, further cutaneous adverse effects from these new triggers may be likely. Also it is interesting to note, while oestrogens typically aggravate lupus, tamoxifen and anastrazole are both anti-oestrogens, demonstrating a paradoxical effect.

Clinically proven to improve the condition of extremely dry, irritated skin.
Rosacea fulminans is a rare facial dermatosis with a female preponderance. It is characterised by the sudden onset of numerous papules, pustules and coalescent nodules localised to the face. Although the aetiology remains unclear, immunological, hormonal and vascular factors have been suggested. To our knowledge there are fifteen reported cases of rosacea fulminans associated with pregnancy, suggesting that hormonal factors may be a trigger. There is no clear evidence as to the mechanism by which pregnancy may trigger this condition. Early and aggressive treatment is essential, yet in the setting of pregnancy a more cautious approach is needed. Effective therapeutic options include retinoids, tetracyclines, anti-androgenic contraceptives and dapsone but all contraindicated in pregnancy. We report two cases of pregnancy-induced rosacea fulminans that were successfully treated post partum with isotretinoin.

Our first patient was a 39-year-old female in her second trimester that presented with a 4-week history of sudden onset severe erythema, pustules and fluctuant nodules affecting her chin and cheeks consistent with a diagnosis of acute rosacea fulminans. She previously suffered from acne vulgaris responsive to tetracyclines. She was treated with oral erythromycin, prednisolone and intralesional triamcinolone throughout her pregnancy, which lead to a significant improvement but still reported intermittent flares. She had an uncomplicated delivery of a healthy boy at term. She was commenced on isotretinoin 20mg daily six weeks post partum. Erythromycin and prednisolone were stopped after a normal ACTH stimulation test. Her skin cleared after 7 months of treatment on isotretinoin (20mg daily for 6 months and 10mg for one month). At six month follow up, her skin remained clear off treatment.

Our second patient is a 32-year-old female who was diagnosed with rosacea fulminans at 17 weeks gestation. She had a history of rosacea, which was well controlled prior to pregnancy. On examination she had inflamed nodules, papules and cysts affecting her face. Treatment with erythromycin, prednisolone and intralesional triamcinolone throughout her pregnancy lead to an improvement but not clearance of rosacea fulminans. She had an uncomplicated delivery of a healthy baby girl at term. Post-partum she was commenced on isotretinoin 10mg daily and continued prednisolone and erythromycin. Her dose was increased to 30mg od and treatment is ongoing with good response. This patient hopes to plan a second pregnancy and there is little in the literature to predict the likelihood of recurrence of her rosacea.

The cause of pregnancy-induced rosacea fulminans is poorly understood and presents a therapeutic challenge for future pregnancies.
NeoStrata®
The Science of Great Skin

Illuminates and brightens pigmented skin

Increases natural cell turnover

Promotes even skin tone

Scientifically advanced, clinically proven technology
Irish Association of Dermatologists
Autumn Meeting 2014

Sponsors & Date for Your Diary

IAD would like to thank the following sponsors and exhibitors for their generous support

AbbVie
Galderma
Janssen-Cilag
Pfizer
Roche
La Roche-Posay
Leo Pharma
NeoStrata
Novartis
Pierre Fabre Dermo-Cosmetique
Beiersdorf
Dermacea
Dermal Labs
GSK
Johnson & Johnson
Meda Ireland
Meda Pharmaceuticals UK
Shire

DATE FOR DIARY...
IAD Spring Meeting
50th Anniversary
23rd – 25th April 2015
Carton House Hotel, Maynooth, Co. Kildare
Picato®. An effective patient-friendly 2-3 day treatment course for Actinic Keratosis®(AK)

*non-hyperkeratotic, non-hypertrophic

75% (n=220) and 93% (n=273) median reduction in actinic keratosis lesion count from baseline at Day 57 on trunk/extremities and face/scalp respectively.

Leo®
Made in Ireland

Abbreviated Prescribing Information for Picato® 150 micrograms/g (mg/g) gel. Please see full SmPC (www.medicines.ie) before prescribing. Presentation: Picato® 150 micrograms/g (mg/g) gel. One tube contain 150 mg (150 microlitres) incglobal medicatval quantity to treat an adult q. Acne and treament is the same as for Picato® 150 micrograms/g (mg/g) gel. Once tubel is applied once daily to the affected area tor 3 consecutive days. Application o thetoute and extremities (500 mg/g). One tube to be applied once daily to affected area for 2 consecutive days. Pandiatric: No relevant use. No dose adjustment required. The contents of one tube covers a treatment area of 25 cm² (5 x 5 cm²). This should be applied to one treatment area of 20 cm². Tube for single use only. Discard after use. Squeeze the gel from the tube onto a fingerpad and spread evenly over the entire treatment area to allow for 5 minutes. Treatment of neck if more than half of the treatment area is located in the upper part of the neck, posology for face and scalp should be used. If more than half of the treatment area is located in the lower part of the neck, posology for trunk and extremities should be used. Wash hands with soap and water immediately after applying gel. In 1 week, patients should wash the fingepad used to apply the gel. Avoid washing and touching treated area for 6 hours after applying gel. After this period, treatment area may be washed with mild soap and water. Gel should not be applied immediately after bathing or swimming or less than 4 hours before bedtime. Treatment area should not be covered with occlusive bandages after applying gel. Optimal therapeutic effect can be assessed after approximately 6 weeks. If treatment area shows an incomplete response at follow-up, treatment should be carefully re-assessed and management re-considered. Clinical data on more than one treatment course of 2 or 3 consecutive days not available. Clinical data on treatment of more than one area not available. Treatment data in immunocompromised patients are not available, but systemic side effects not expected since incglobal medicatval quantity is not absorbed systemically. Contraindications: Hyperreactivity to any of the components. Pemiscellaneous and warnings: Avoid contact with eyes. If accidental exposure occurs, flush eyes with large amounts of water and seek medical advice as soon as possible. Eye disorders such as eye pain, eye lid oedema and periocular oedema expected to occur after accidental exposure. Gel must not be ingested. If accidental ingestion occurs, drink large amounts of water and seek medical advice. Admission not recommended until skin healed from treatment with any previous medicinal product or surgery. Do not apply to open wounds or damaged skin. Do not use near the eyes, inside nostrils, inside ears or on lips. Local skin reactions (LSRs) such as erythema, hyperkeratosis and crusting should be expected to occur during and after treatment application. LSRs are transient and typically occur within one day of treatment initiation and peak in intensity up to one week following completion of treatment. LSRs typically resolve within 2 weeks of treatment initiation. When treating face and scalp and within 4 weeks of treatment initiation when treating trunk and extremities. Treatment effect may not be adequately assessed until resolution of LSRs. Incglobal medicatval quantity did not demonstrate any potential for photo irritation or photoallergic effects during studies to assess the effect of UV irradiation. However, due to nature of disease, excessive exposure to sunlight (including sunlamps and tanning beds) should be avoided or minimized. Clinically significant lesions or suspicious lesions for malignancy should be biopsied to determine appropriate treatment. Drug Interactions: Interactions with systemically absorbed medicinal products considered unlikely as gel is not absorbed systemically. Pregnancy and lactation: No data from use of incglobal medicatval quantity in pregnant women. Animal studies showed slight embryotoxic toxicity. Risks to humans receiving cutaneous treatments with incglobal medicatval quantity are considered unlikely as no systematic absorption. As a precautionary measure, it is preferable to avoid use of the gel during pregnancy. No effects on the breast-fed newborns/infant anticipated. Instruct nursing mother that physical contact between the newborn/infant and the treated area should be avoided for 6 hours after application of gel. Side effects: Most frequently reported adverse drug reactions (ADRs) are LSRs. Following application of incglobal medicatval quantity, most patients (50%) experienced one or more LSRs. ADRs observed for face and scalp (500 mg/g). Very common: Application site pruritus, erosion, vesicles, swelling, exudation, scab, erythema, pain (including burning). Common: Headache, eye irritation/periorbital oedema, application site infection, pruritus, irritation. Uncommon: Eye pain, application site excoriation, paraesthesia, sore Application site swelling on the face or scalp may cause erythema to the eye area. ADRs observed for trunk and extremities (500 mg/g): Very common: Application site pruritus, erosion, vesicles, swelling, exudation, scab, erythema, pain (including burning). Common: Application site infection, pruritus, irritation. Uncommon: Application site paraesthesia, flare, warmth. See SmPC for a full list of side effects. Precautions for storage: Store in a refrigerator (2°C–8°C). Legal category: POM Product Licence Number and Holder: Picato® 150 micrograms/g gel - EUP/2012/005/011, Raabo 250 micrograms/g gel - EUP/2012/005/011, Raabo 500 micrograms/g gel - EUP/2012/005/011, Raabo 1000 micrograms/g gel - EUP/2012/005/011, Raabo LEO Pharma A/S, Billund, Denmark. Last updated: November 2013. Further information can be found in the Summary of Product Characteristics or from LEO Pharma, Copenahgen, DK-2200. Telephone: 018496624 or email medical-info@leo-pharma.com® Registered Trademark

Irish Association of Dermatologists
Spring Meeting 2014

Deirdre Callaghan AbbVie, Burrows Cup Winner Dr Genevieve Kelly, IAD President Dr Rosemarie Watson

Dr Andrea Corry, Dr Olivia Dolan, Dr Richard Corry, Dr Susannah Hoey & Mr Richard Best

Dr Billy O’Connor, Dr Rosemarie Watson & guest speaker Dr Alex Sekulic
Irish Association of Dermatologists
Spring Meeting 2014

Dr Keith Armstrong & Dr Deirdre Kerr

Dr Kevin McKenna, Dr David Todd & Dr Hilary Jenkinson

Dr Marina O’Kane, Prof Frank Powell, Dr Sinead Collins & Dr Maureen Connolly
Irish Association of Dermatologists
Spring Meeting 2014

Dr Olivia Dolan, Dr Deirdre Kerr & Dr Richard Corry

Dr Oonagh Molloy, Dr Nicola Ralph, Dr Caoimhe Fahy & Dr Siobhan McCarthy
TRECLINAC: ABBREVIATED PRESCRIBING INFORMATION